Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCA-010 in Treatment-Naïve Localized Prostate Cancer
NCT04097002Phase 2Active, not recruiting
- Sponsor
- ORCA Therapeutics
- Start
- Nov 2019
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5-D24RGD in prostate cancer (PCa), sponsored by ORCA Therapeutics. Started Nov 2019; status: active, not recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04097002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097002.